Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $49.3 million.

  • Fennec Pharmaceuticals' Liabilities and Shareholders Equity fell 16.39% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.5 million, marking a year-over-year decrease of 14.97%. This contributed to the annual value of $44.9 million for FY2024, which is 67.31% up from last year.
  • Per Fennec Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $49.3 million for Q3 2025, which was up 9.77% from $44.9 million recorded in Q2 2025.
  • Fennec Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $69.2 million during Q1 2024, with a 5-year trough of $15.6 million in Q2 2022.
  • For the 3-year period, Fennec Pharmaceuticals' Liabilities and Shareholders Equity averaged around $42.3 million, with its median value being $44.9 million (2024).
  • As far as peak fluctuations go, Fennec Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 44.63% in 2022, and later surged by 224.95% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Liabilities and Shareholders Equity stood at $26.0 million in 2021, then rose by 16.93% to $26.9 million in 2022, then declined by 0.28% to $26.9 million in 2023, then spiked by 67.31% to $44.9 million in 2024, then decreased by 16.39% to $49.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $49.3 million for Q3 2025, versus $44.9 million for Q2 2025 and $46.4 million for Q1 2025.